Board & Management


Graeme Kaufman
Non Executive Chairman

Graeme has wide ranging, hands on experience across the biotechnology sector, spanning technical, commercial and financial areas. He has significant Board experience with ASX listed companies, in both executive and non-executive roles. He spent 32 years in various roles at CSL Limited, Australia’s largest biopharmaceutical company and was one of the driving forces behind the listing of the company on the ASX.He has also held senior roles since that time at companies such as Circadian Technologies, Amrad and Mesoblast. Graeme is also a non-executive director of Cellmid Limited.

Reo Shigeno

Reo is the Chief Financial Officer of Healthy Clinical research Pty Ltd, a subsidiary of I'rom Holdings Group where he manages I’rom Group’s investment portfolios. He has in the past been a Private Banker with ANZ Private Bank and a Japanese Relationship Manager with the ANZ Banking Group.

Alan Fisher

Alan has extensive business and corporate experience and in particular has expertise in financial and operations restructuring. Mr Fisher is currently the Managing Director of DMC Corporate Pty Ltd (a business which specialises in restoring and enhancing stakeholder value) and has previously held the position of CEO of Pental Limited, where he was instrumental in its successful restructuring. He has also held the position of Managing Director of HRL Limited, which involved a successful relisting, and was a Corporate Finance Partner of Coopers & Lybrand. Mr Fisher holds a Bachelor of Commerce from Melbourne University and is a Fellow of the Institute of Chartered Accountants.

Hugh Burrill

Mr Burrill has held a number of senior pharmaceutical industry executive roles, including Corporate Vice President, Global Pharma Research and Development for Hospira Inc., one of the top 10 generic companies globally.  In this role he was responsible for overall pipeline portfolio management, and research and development of generic and speciality pharmaceuticals.  Prior to this he held other senior international roles within Hospira and the original Mayne Pharma.  He currently provides consulting services in the area of pharmaceutical strategic management, product development, regulatory affairs and intellectual property.  Additionally he previously served as Managing Director of CCH Pharma Pty Ltd.  Since 2007 he has been Non-Executive Director and Deputy Chair (July 2015) of Nova Aerospace Pty Ltd.

Mary Sontrop

Mary has considerable experience in the biopharmaceutical sector across manufacturing operations, quality and business integration. During her 28 years with CSL Limited (CSL) she participated in CSL’s major international acquisitions being primarily responsible for the turnaround of unprofitable manufacturing operations, subsequently delivering a globally integrated manufacturing network spanning four countries. As head of CSL’s Australia and New Zealand pharmaceutical business she and her team delivered one of Australia’s most successful immunization programs; human papilloma virus and achieved FDA (US Food &Drug Administration) approval to manufacture and export CSL’s seasonal and pandemic influenza vaccines.


Joanna Johnson
Joanna Johnson
Chief Financial Officer, Company Secretary

Joanna is a chartered Accountant with many years of senior finance roles in the pharmaceuticals industry.  Her first Pharma role was at FH Faulding & Co, progressing to Regional Finance Director, Asia Pacific, with Hospira.  Her most recent role was as CFO of Generic Health, a subsidiary of Lupin. 

David Sparling
Dr David Sparling
Corporate and Business Development, Company Secretary

Dr. David Sparling joined IDT in May 2013 as Vice President Legal & Corporate Development. He is responsible for identifying and executing on major transactions in line with IDT's strategy for growth and expansion. He also assists in business development, customer management, legal and compliance.  David holds honours level degrees in both Veterinary Science and in Law.  He is an experienced senior executive, having held roles at CEO and Chairman level in ASX listed companies, and is a Chartered Company Secretary.

Danielle Savaglio
Danielle Savaglio
Vice President, People, Change & Internal Communications

As a registered consulting psychologist specialising in organisation development Danielle brings a wealth of experience and key skills relevant for IDT as the organisation continues to grow and transform.  Previously, Danielle held senior HR business partner roles with responsibilities spanning EMEA, APAC and the Americas while working for Dako an Agilent Technologies company.  Before this time, she held senior consulting roles in Australia and France, working on national and global projects for multinationals in the areas of talent, leadership and organisation development.

Paul Loria
Dr Paul Loria
Vice President, Quality & Regulatory Management

Paul has over 16 years experience in the pharmaceutical industry in both sterile injectable and active pharmaceutical ingredients for most markets around the world.  Paul has managed and directed small and large teams throughout his career and has spent 9 years in various Regulatory Affairs roles where he gained regulatory approval for new finished dosage manufacturing sites, new active pharmaceutical ingredients, manufacturing and testing changes.  Paul joins IDT with a wealth of experience in the areas of strategy and continuous improvement, regulatory, tech transfer and operations.